+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Stomach Cancer Treatment Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 184 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012198
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The stomach cancer treatment market is undergoing a period of change, characterized by rapid advancements in diagnostics, therapeutic innovation, and collaboration across stakeholders. Senior leaders must adapt to policy, clinical, and operational shifts to maximize value and ensure continued access to effective therapies.

Market Snapshot: Stomach Cancer Treatment Market

The stomach cancer treatment market grew from USD 5.55 billion in 2024 to USD 6.10 billion in 2025 and is projected to expand at a CAGR of 9.88%, reaching USD 11.79 billion by 2032. This robust growth reflects intensifying R&D, evolving regulatory dynamics, and rising adoption of personalized treatment strategies across global regions.

Scope & Segmentation of the Stomach Cancer Treatment Market

This report delivers a comprehensive evaluation of treatment modalities, regional trends, industry leaders, and emerging technologies influencing the landscape.

  • Treatment Types: Chemotherapy (fluorouracil-based, platinum-based, taxane-based), Immunotherapy (CTLA-4 inhibitors, PD-1 inhibitors), Radiotherapy (brachytherapy, external beam), Surgery (partial gastrectomy, total gastrectomy), and Targeted Therapy (EGFR, HER2, VEGF inhibitors).
  • Route of Administration: Intravenous administration as well as oral formulations, balancing patient adherence and care model needs.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy settings, serving in-hospital, ambulatory, and remote patients.
  • Stage: Stratification covers Stage I through IV, addressing both early curative and advanced palliative interventions.
  • End User: Homecare, hospitals, and specialty clinics, emphasizing the need for tailored clinical support structures.
  • Histologic Type: Adenocarcinoma, carcinoid tumors, GIST, and lymphoma, informing precise therapy selection and diagnostic workflow.
  • Regional Segments: Americas—United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru. Europe, Middle East & Africa—United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya. Asia-Pacific—China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan.
  • Leading Companies: F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Sanofi S.A., Pfizer Inc., Amgen Inc.

Key Takeaways for Decision-Makers

  • Personalized approaches, utilizing molecular diagnostics and advanced imaging, are replacing legacy protocols and redefining patient pathways.
  • Immunotherapy and targeted agents continue to challenge established regimens, compelling a shift toward combination therapies and multidisciplinary collaboration.
  • Integration of real-world data is streamlining the translation of clinical breakthroughs, accelerating their adoption in varied healthcare settings.
  • Digital health platforms and remote monitoring tools are reshaping patient support and resource allocation, particularly for oral medications and homecare models.
  • Supply chain strategies are being retooled as regulatory and tariff pressures complicate sourcing and pricing, underscoring the importance of proactive engagement.
  • Regional variances in reimbursement, regulatory review, and infrastructure development impact market access and require localized strategies to ensure treatment continuity.

Assessing Tariff Impact on Cost and Accessibility

Recent tariff adjustments in the US have influenced importation costs for active pharmaceutical ingredients and essential bioprocessing equipment. Manufacturers are prioritizing local sourcing and regional partnerships to maintain supply chain resilience and heading off potential pricing volatility. These changes are leading to a reevaluation of procurement strategies, formulary placement, and patient assistance programs, especially where patient cost exposure is high. Stakeholders responding quickly to these dynamics can help safeguard affordability and care continuity for gastric cancer patients.

Research Methodology & Data Sources

This report leverages a blend of exhaustive secondary research and primary interviews with oncologists, pharmacoeconomists, and supply chain specialists. Structured data collection and triangulation methods validate findings, while independent expert reviews ensure the analysis is robust and actionable.

Why This Report Matters to Stomach Cancer Ecosystem Leaders

  • Empowers you to navigate an increasingly complex therapeutic landscape through up-to-date segment and technology analyses.
  • Enables actionable planning for clinical, operational, and commercial teams by delivering clarity on regional shifts, pipeline developments, and regulatory factors.
  • Supports informed investment and resource allocation decisions along the entire value chain, from R&D through market access.

Conclusion

Stomach cancer treatment is evolving through innovation, regulatory developments, and supply chain dynamics. This report equips senior stakeholders with the strategic insights needed to drive performance, adapt swiftly, and deliver improved outcomes for patients.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Rapid adoption of PD-1 and PD-L1 inhibitors in first-line gastric cancer treatment
5.2. Integration of molecular biomarker screening to personalize gastric cancer therapies
5.3. Increasing use of liquid biopsy for early detection and monitoring of tumor recurrence
5.4. Development of FGFR2 targeting agents for advanced gastric cancer patients with receptor amplification
5.5. Expansion of minimally invasive robotic surgery to improve postoperative outcomes in gastric cancer
5.6. Utilization of real-world evidence to optimize treatment sequencing in metastatic gastric cancer
5.7. Growth of combination immunotherapy and chemotherapy regimens in advanced stomach cancer management
5.8. Rising investment in AI-enabled endoscopic systems to enhance early gastric cancer diagnosis accuracy
5.9. Emergence of CAR-T cell therapies targeting Claudin 18.2 in refractory gastric tumors
5.10. Impact of evolving reimbursement policies on accessibility of novel gastric cancer treatments across markets
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Stomach Cancer Treatment Market, by Treatment Type
8.1. Chemotherapy
8.1.1. Fluorouracil-Based
8.1.2. Platinum-Based
8.1.3. Taxane-Based
8.2. Immunotherapy
8.2.1. Ctla-4 Inhibitors
8.2.2. Pd-1 Inhibitors
8.3. Radiotherapy
8.3.1. Brachytherapy
8.3.2. External Beam
8.4. Surgery
8.4.1. Partial Gastrectomy
8.4.2. Total Gastrectomy
8.5. Targeted Therapy
8.5.1. Egfr Inhibitors
8.5.2. Her2 Inhibitors
8.5.3. Vegf Inhibitors
9. Stomach Cancer Treatment Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
10. Stomach Cancer Treatment Market, by Distribution Channel
10.1. Hospital Pharmacy
10.2. Online Pharmacy
10.3. Retail Pharmacy
11. Stomach Cancer Treatment Market, by Stage
11.1. Stage I
11.2. Stage Ii
11.3. Stage Iii
11.4. Stage Iv
12. Stomach Cancer Treatment Market, by End User
12.1. Homecare
12.2. Hospitals
12.3. Specialty Clinics
13. Stomach Cancer Treatment Market, by Histologic Type
13.1. Adenocarcinoma
13.2. Carcinoid Tumors
13.3. Gist
13.4. Lymphoma
14. Stomach Cancer Treatment Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Stomach Cancer Treatment Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Stomach Cancer Treatment Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche AG
17.3.2. Bristol-Myers Squibb Company
17.3.3. Merck Sharp & Dohme Corp.
17.3.4. AstraZeneca PLC
17.3.5. Novartis AG
17.3.6. Takeda Pharmaceutical Company Limited
17.3.7. Daiichi Sankyo Company, Limited
17.3.8. Sanofi S.A.
17.3.9. Pfizer Inc.
17.3.10. Amgen Inc.
List of Tables
List of Figures

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Stomach Cancer Treatment market report include:
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Merck Sharp & Dohme Corp.
  • AstraZeneca PLC
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • Amgen Inc.

Table Information